U.S. markets open in 3 hours 40 minutes
  • S&P Futures

    3,922.50
    0.00 (0.00%)
     
  • Dow Futures

    31,989.00
    +73.00 (+0.23%)
     
  • Nasdaq Futures

    13,242.50
    -59.50 (-0.45%)
     
  • Russell 2000 Futures

    2,299.20
    +14.10 (+0.62%)
     
  • Crude Oil

    63.40
    +0.18 (+0.28%)
     
  • Gold

    1,791.90
    -6.00 (-0.33%)
     
  • Silver

    28.19
    +0.26 (+0.94%)
     
  • EUR/USD

    1.2225
    +0.0057 (+0.46%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    22.06
    -1.05 (-4.54%)
     
  • GBP/USD

    1.4160
    +0.0019 (+0.14%)
     
  • USD/JPY

    106.0630
    +0.1810 (+0.17%)
     
  • BTC-USD

    49,365.53
    -1,876.75 (-3.66%)
     
  • CMC Crypto 200

    988.69
    -5.97 (-0.60%)
     
  • FTSE 100

    6,700.49
    +41.52 (+0.62%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Recap: Neurocrine Biosciences Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 13.33% year over year to $0.91, which beat the estimate of $0.54.

Revenue of $247,900,000 rose by 1.56% from the same period last year, which missed the estimate of $262,400,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 04, 2021

View more earnings on NBIX

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1046/39561

Recent Stock Performance

52-week high: $136.26

52-week low: $72.14

Price action over last quarter: Up 30.79%

Company Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.